Elicio Therapeutics Reports Post-Hoc Phase 2 AMPLIFY-7P Study; Stock Down Over 70%
Elicio Therapeutics (ELTX) reported post-hoc results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P in resected mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the overall intent-to-treat population, which the company attributed partly to more R1 resections in the ELI-002 arm. In R0 patients (n=121), DFS improved (HR 0.65, p=0.048; median 23.8 vs 12.8 months). Elicio plans a refined Phase 3 focused on R0 patients and additional dosing, and said current cash su
Post-hoc DFS benefit in R0-resected PDAC patients and immune-response correlation support a refined Phase 3 focus, but primary endpoint miss keeps risk elevated.
Elicio reported AMPLIFY-7P Phase 2 results: primary DFS missed overall, but post-hoc R0-resected patients showed HR 0.65 (p=0.048).
Near-term sentiment likely mixed: downside pressure from primary endpoint miss may persist, while upside attempts could emerge on the R0-focused Phase 3 plan and hazard-ratio signal.
Background
AMPLIFY-7P is a Phase 2 adjuvant study of ELI-002 7P (mKRAS-specific T-cell stimulation) in resected pancreatic ductal adenocarcinoma, where relapse risk remains high.
Why it matters
The key new trading-relevant elements are (1) the quantified post-hoc DFS benefit in R0-resected patients, (2) the immune-response/DFS correlation supporting biological activity, and (3) the stated plan to refine Phase 3 toward R0-resected patients and additional dosing—tempered by the primary endpoint miss and the need for future financing.
Market relevance
Traders will likely reprice ELTX around the probability-weighted chance of a successful, prospectively designed Phase 3 in the R0-resected subgroup, while monitoring financing risk into 4Q 2026.
Market effects
Reinforces the adjuvant PDAC immunotherapy read-through that patient selection (R0 resection) may be critical for trial success.
Primarily US biotech sentiment; limited direct regional spillover beyond small-cap healthcare risk.
Modest global relevance as it is a single-company Phase 2 update with a development strategy refinement rather than a platform-wide regulatory or commercial event.
Alternative perspectives
Post-hoc findings may be vulnerable to selection bias and multiplicity; the primary endpoint miss suggests the overall program may not translate without stronger prospective confirmation.
The article flags a surgical-margin imbalance (more R1 patients in the ELI-002 arm) and highlights that additional financing will be required—both can dominate valuation more than the post-hoc efficacy signal.
Key entities
- companyElicio Therapeutics, Inc.
Reported Phase 2 AMPLIFY-7P post-hoc efficacy signals and outlined a refined Phase 3 strategy plus funding outlook.
- programELI-002 7P
mKRAS-specific T-cell stimulation approach evaluated in the adjuvant setting; post-hoc R0 benefit reported.
- clinical_trialAMPLIFY-7P
Phase 2 study in resected PDAC; primary DFS missed overall but post-hoc R0 analysis showed benefit.
